Skip to content

All Press Releases

CORRECTION: Clarification and extended information on previous press release regarding convertible loans and their structure.

Malmö, 24 August 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA), ("Pila Pharma" or the "Company") announces a correction regarding the press release "PILA PHARMA announces capital infusion via convertible loans" which was published earlier today, 24 August 2023. The correction refers to the fact that the press release lacked significant information on…

Read more

PILA PHARMA announces capital infusion via convertible loans

Malmö, 24 August 2023 Download the press release as PDF here The board of Pila Pharma AB (publ) has decided to immediately secure additional funds via convertible loan agreements to sponsor the next clinical trial applications. With the recent news that our tablets manufactured in 2021 are cleared by the manufacturer for use in phase 1 or 2a studies, Pila…

Read more

PILA PHARMA publishes interim report (1 April – 30 June 2023)

Malmö, 23 August, 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for      the period April – June 2023. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information/ SUMMARY OF INTERIM REPORT Second quarter (1 April- 30 June 2023) Operating income amounted to TSEK 301 (651) The operating result…

Read more

Contact us

Subscription for press releases
Back To Top